Dr. Sullivan's response to Dr. Toogood's editorial.

T. Sullivan

DOI: https://doi.org/10.1016/0091-6749(89)90088-2

IF: 14.29

1989-03-01

Journal of Allergy and Clinical Immunology

Abstract:

What problem does this paper attempt to address?

Retrospective biomonitoring: a hundred years of environmental pollution at selected areas in Slovakia.

K. Mičieta,G. Murín

Abstract:Tetrade analyses of Calluna vulgaris from herbarium specimens showed significant differences in the frequency of aborted pollen tetrads over the last 100 years within various parts of Slovakia. Specifically, we observed changes in the dynamics of pollution peaking in the year 1965 in heavily polluted industrial area of an aluminium factory in Ziar nad Hronom.
Refinement of reference limits for alanine aminotransferase in the Korean elderly population.

S. Park,Ha Young Park,J. Kang,Jin Se Park,K. J. Shin,J. G. Lee,C. H. Kim,K. Suk,D. J. Kim,H. Lee

DOI: https://doi.org/10.1016/j.clinbiochem.2012.10.004

IF: 3.625

2013-02-01

Clinical Biochemistry

Abstract:
Community Pop‐Up Clinic: Cascade of Care and HCV Treatment of Vancouver's Inner‐City PWID Populations

Shana Yi,Christina Wiesmann,David Truong,Shawn Sharma,Brian Conway

DOI: https://doi.org/10.1111/jvh.14023

2024-10-21

Journal of Viral Hepatitis

Abstract:Elimination of HCV infection as a public health concern by the end of this decade will require a concerted effort in all target populations, including drug‐users in the inner‐city. Several strategies have been proposed to identify, engage and provide HCV‐infected residents with antiviral therapy and maximise treatment and cure achievement. This study aims to assess the effectiveness of a multidisciplinary approach in delivering HCV treatment to people who inject drugs (PWID) within Vancouver's inner city. We have evaluated a novel approach, the Community Pop‐Up Clinic, for its ability to promote access to care and uptake of HCV therapy, with additional analyses of HCV reinfection and opioid‐related mortality. From January 2021 to August 2023, we evaluated 1968 individuals. 620 (31.5%) were found to carry HCV antibodies and of these, 474 (76.5%) were found to be viremic. Treatment engagement has been secured in 387 (81.6%). 326 (84.2%) have started treatment, 60 in the pre‐treatment phase and 1 died of an overdose in pre‐treatment. Of 326, 302 completed treatments, 18 are currently on treatment and 1 died of an overdose. Of 302 who completed treatment, 286 confirmed as cured (SVR 12), 16 are awaiting SVR 4, 2 had documented virologic relapse and 1 was reinfected. Three patients withdrew from treatment. By mITT, the cure rate is 286/288 (99.3%). We documented 2 overdose deaths over 326 PY. The data presented validates multidisciplinary programs such as ours aimed at treating HCV in inner‐cities and highlights societal benefits that could be achieved including lower overdose death rates.

gastroenterology & hepatology,infectious diseases,virology
Challenges and Opportunities for Treating Hepatitis C Amongst People Who Use Drugs: Experience of an Integrated Mobile Clinic in Baltimore City

Amanda Rosecrans,Robert Harris,Anne St Clair,Molly Rice,Meredith Zoltick,Catherine Willman,Anne King,Meredith Kerr,Kathleen R. Page

DOI: https://doi.org/10.1111/jvh.14038

2024-11-28

Journal of Viral Hepatitis

Abstract:Progress in treating chronic hepatitis C virus (HCV) infection has been slow amongst people who use drugs (PWUD). This study describes the HCV treatment cascade amongst people accessing a mobile clinic offering integrated low‐threshold buprenorphine and infectious disease services in Baltimore City. From May 1, 2021, to December 31, 2022, 560 people had a rapid HCV antibody test, of whom 201 (36%) had a positive result and amongst those, 117 (58%) had an HCV RNA test performed, 81 (40%) had a documented positive RNA, 45 (22%) were prescribed medication, 42 (21%) started medication, 32 (16%) completed medication, 22 (11%) had blood work to assess for sustained virologic response and 20 (10%) had a documented cure. Challenges including housing instability, insurance barriers and lack of venous access limit progress in this cascade. Providing integrated care models to meet the needs of PWUD in the community is necessary but not sufficient to make progress in improving HCV treatment. Removal of insurance restrictions, availability of point‐of‐care HCV RNA testing, development of rapid HCV treatment guidelines and development of long‐acting injectable HCV treatment are needed to move towards a same‐day, one‐time test and treat model of care.

gastroenterology & hepatology,infectious diseases,virology
An Analysis of Social Determinants of Health and Their Implications for Hepatitis C Virus Treatment in People Who Inject Drugs: The Case of Baltimore

Luis A Gonzalez Corro,Katie Zook,Miles Landry,Amanda Rosecrans,Robert Harris,Darrell Gaskin,Oluwaseun Falade-Nwulia,Kathleen R Page,Gregory M Lucas

DOI: https://doi.org/10.1093/ofid/ofae107

2024-03-02

Open Forum Infectious Diseases

Abstract:Abstract Background Sixty-eight percent of the nearly 3.5 million people living with hepatitis C virus (HCV) in the United States are people who inject drugs (PWID). Despite effective treatments, uptake remains low in PWID. We examined the social determinants of health (SDoH) that affect the HCV care cascade. Methods We conducted a secondary analysis of data from 720 PWID in a cluster-randomized trial. We recruited PWID from 12 drug-affected areas in Baltimore. Inclusion criteria were injection in the prior month or needle sharing in the past 6 months. Intake data consisted of a survey and HCV testing. Focusing on SDoH, we analyzed self-report of (1) awareness of HCV infection (in those with active or previously cured HCV) and (2) prior HCV treatment (in the aware subgroup). We used descriptive statistics and logistic regression for statistical analyses. Results The 342 participants were majority male and Black with a median age of 52 years. Women were more likely to be aware of their status but less likely to be treated. Having a primary care provider and HIV-positive status were associated with increased awareness and treatment. Unhoused people had 51% lower odds of HCV treatment. People who reported that other PWID had shared their HCV status with them had 2.3-fold higher odds of awareness of their own status. Conclusions Further study of gender disparities in HCV treatment access is needed. Increased social support was associated with higher odds of HCV treatment, suggesting an area for future interventions. Strategies to identify and address SDoH are needed to end HCV.

immunology,infectious diseases,microbiology
Improving Access to Hepatitis C Treatment Using Clinical Pharmacist Services in an Uninsured, At-Risk Population at a Community Health Center

Lynn S Fitzgerald,Barbara E Johnston,Bina Patel,Tracy Stillwell,Lynn S. Fitzgerald,Barbara E. Johnston

DOI: https://doi.org/10.1353/hpu.2021.0142

2021-01-01

Journal of Health Care for the Poor and Underserved

Abstract:While published cure rates for new hepatitis C virus (HCV) treatments exceed 90%, barriers such as cost, medication access, housing or phone service instability, and substance use complicate medication adherence for uninsured, at-risk populations. Lincoln Community Health Center (LCHC) Pharmacy, in collaboration with primary care providers and care coordination professionals, implemented clinical pharmacist services to facilitate treatment of HCV infection in uninsured patients using manufacturers' patient assistance programs (PAP). Eighty-four (84) uninsured patients initiated treatment at LCHC using PAP during the first two years of the program. Nearly all patients (65/67 or 97%) who completed lab monitoring at 12 weeks post-treatment achieved undetectable viral load or a sustained virologic response (SVR-12), considered a proxy for cure. Successfully treating HCV infection in an uninsured, at-risk population may be achieved in a safety-net community health center by incorporating clinical pharmacist services into a team-based model.

public, environmental & occupational health,health policy & services
High prevalence of hepatitis B virus susceptibility among persons undergoing community-based hepatitis C virus treatment

Catherine Campusano,Rachel Kanner,Claire McDonell,Meghan Morris,Maria Duarte,Jennifer C Price

DOI: https://doi.org/10.1186/s12954-024-00942-x

2024-01-29

Abstract:Background: Due to shared modes of transmission, coinfection with hepatitis B virus (HBV) and hepatitis C virus (HCV) is common, and HBV vaccination is recommended for all persons with HCV who remain susceptible to HBV. To identify potential gaps in HBV vaccination among this high-risk population, we aimed to determine the patterns of HBV susceptibility in persons undergoing community-based HCV treatment. Methods: We performed a cross-sectional study within two community-based HCV treatment programs in an urban US setting. Participants were identified for HCV screening and confirmatory testing via street-outreach recruitment directed at persons experiencing homelessness and currently using drugs. Participants were excluded if HBsAg was reactive. Cohort characteristics were obtained via intake surveys and descriptive analysis was performed by exposure status. Results: Among 150 participants without chronic HBV receiving community-based HCV treatment, 43% had evidence of prior HBV infection, 26% were immune from vaccination, and 31% were non-immune. Among the subset of the cohort reporting current injection drug use (IDU) (N = 100), 31% (n = 10) of those aged 24-40 and 47% (n = 23) of those aged 41-57 remained susceptible to HBV infection. By contrast only two participants aged 58-74 were HBV non-immune (11%), with 84% immune due to prior exposure. Conclusions: Our data reflect a high prevalence of HBV susceptibility among persons undergoing community-based HCV treatment. Although younger patients were more likely to be immune due to vaccination, a high proportion remained non-immune to HBV, particularly among those reporting current IDU. Our data reflect a gap in HBV vaccination among younger persons with HCV and suggest a potential role for co-localizing HBV vaccination with community-based HCV screening and treatment.
2942. Successful Screening, Linkage to Care, and Treatment of Hepatitis C in a Tiny Shelter Encampment on Veterans Affairs Grounds

Cassandra C Lautredou,Kimberly A Lynch,Katherine Stricker,Peter Capone-Newton,Matthew McCoy,Jenna Kawamoto,Arpan Patel,Michele Seckington,Debika Bhattacharya

DOI: https://doi.org/10.1093/ofid/ofad500.181

2023-11-27

Open Forum Infectious Diseases

Abstract:Abstract Background Persons experiencing homelessness have a high prevalence of hepatitis C virus (HCV) infection and multiple barriers to diagnosis and treatment. We implemented and evaluated a universal HCV screening and HCV care coordination and treatment program for Veterans living at a tiny shelter encampment on the West Los Angeles Veterans Affairs campus. Hepatitis C Cascade of Care All patients who completed treatment and obtained end of treatment lab work achieved SVR12, excluding Veterans who were lost to follow up (LTFU) and/or non-adherent (NA) (n=5), on treatment (n=4), or SVR12 pending (n=5). Methods We implemented a low-barrier to entry HCV treatment program for Veterans experiencing homelessness (VEH) that spanned April 2020-Dec 2021 (pre-intervention) and Jan 2022-April 2023 (post-intervention). The intervention involved a novel e-consult direct-to-treatment program facilitated by pharmacists and referral to ID/GI clinics (if ineligible for e-consult) and extensive engagement by encampment providers, including provision of direct-acting antivirals (DAAs) in weekly installments. Prior to the intervention, management was achieved solely through ID/GI clinic referrals. We evaluated HCV prevalence, along with linkage to care, treatment initiation, and sustained virologic response (SVR) of this novel program pre-and post-intervention. Data, including demographics, medical history healthcare visits, and other laboratory values were abstracted from the electronic medical record. Descriptive statistics were used to characterize prevalence of HCV and other covariates. Results Of the 704 Veterans who sheltered at the encampment at some point from April 2020-April 2023, 587 underwent HCV antibody screening (83%). Of those, 20% (120/587) were HCV Ab positive and 44% (53/120) had HCV viremia. Median age of those who were viremic was 64 years, 100% were male, 32% (17/53) were Black, 9% (5/53) Hispanic, and 58% (31/53) White. Pre- and post-intervention, 25 and 28 Veterans with HCV viremia were identified, 11 and 21 Veterans were linked to care (44% and 75%), 4 and 20 initiated DAAs (36% and 95%), and 1 and 6 achieved SVR (25% and 30%). Nine patients are currently on treatment (n=4) or pending SVR12 (n=5). Conclusion After an intervention involving e-consult and encampment provider engagement in VEH, 75% of Veterans with HCV viremia were linked to care, compared to 44% of Veterans prior to the intervention. Our program demonstrates the feasibility of encampment-based HCV screening, linkage to care and treatment. Disclosures Debika Bhattacharya, MD, MSc, Gilead Sciences: Grant/Research Support

immunology,infectious diseases,microbiology
Acceptability and Effectiveness of Hepatitis C Care at Syringe Service Programs for People Who Inject Drugs in New York City

Brandon Muncan,Ashly E. Jordan,David C. Perlman,David Frank,Danielle C. Ompad,Suzan M. Walters

DOI: https://doi.org/10.1080/10826084.2021.1892142

2021-03-07

Abstract:Introduction/Objectives: The incidence of hepatitis C (HCV) infection is rising among people who inject drugs (PWID). Even in the context of known HCV prevention and treatment strategies, some PWID remain unengaged in HCV care. This study aimed to identify and characterize experiences and perceptions of PWID regarding the acceptability and effectiveness of HCV testing and treatment at a local syringe service program (SSP). Methods: A total of 36 PWID participated in semi-structured interviews at an SSP in New York City. Interviews were audio-recorded, transcribed, and coded by three coders, following a constructivist grounded theory approach. Relevant themes were identified as they emerged from the data. Results: Interviews with PWID revealed three themes related to the impact of SSPs on HCV care: (1) non-stigmatizing SSP environments, (2) the role of SSPs in improving HCV knowledge, and (3) acceptability of SSPs as sites for HCV care among PWID. Discussion: This paper contributes to the ongoing understanding that SSPs provide a well-accepted source of HCV services for PWID. Participants believed that SSPs are accessible and effective sites for HCV care, and suggested that stigma among PWID continues to affect receipt of HCV care in traditional settings. Conclusions: Understanding attitudes and beliefs of PWID regarding the effectiveness of SSPs as sites for HCV care is crucial for the development of focused strategies to reduce HCV transmission, and to ultimately achieve HCV elimination. Given this, further research is warranted investigating how best to improve HCV care at harm reduction sites such as SSPs.

psychiatry,substance abuse,psychology
Findings from a Project Which Established Hepatitis C Point-of-Care Testing and Linkage to Care at a Homelessness Service in Adelaide, Australia, 2021–2022

Erin M. McCartney,Joshua Dawe,Lucy Ralton,Jeffrey Stewart,Jacqueline A. Richmond,Alan Wigg,Victoria Cock,Edmund Y. Tse,Tom Rees,David Shaw,Catherine Ferguson

DOI: https://doi.org/10.3390/v16121882

2024-12-05

Viruses

Abstract:Background: Point-of-care hepatitis C virus (HCV) testing streamlines testing and treatment pathways. In this study, we established an HCV model of care in a homelessness service by offering antibody and RNA point-of-care testing. Methods: A nurse and peer-led HCV model of care with peer support were implemented between November 2021 and April 2022 at a homelessness service in Adelaide, Australia. All clients of the service were eligible to participate. Clients were offered an initial antibody point-of-care test, and antibody positive clients were immediately offered RNA point-of-care testing. Clients who tested RNA positive were linked to a viral hepatitis nurse for treatment. Results: A total of 230 clients received an HCV antibody point-of-care test, of which 68 (30%) were antibody positive and 11 (5%) were RNA positive. Of these, seven (64%) clients successfully completed treatment and five (45%) received a sustained virological response (SVR) test to confirm cure. Conclusions: We successfully established HCV testing and a treatment pathway at a homelessness service using HCV antibody and RNA point-of-care testing. The high testing uptake underscores the utility of HCV point-of-care testing when establishing HCV testing and treatment pathways. The low RNA positivity suggests that an initial HCV antibody test was cost-effective, and the four clients diagnosed with chronic HCV who were lost to follow-up indicate a need for enhanced treatment support.

virology
A Review of Studies on HIV Pre-Exposure Prophylaxis in Community Pharmacies in States with Restrictive Pharmacist Prescription Authority in the United States

Hongmei Wang,Dominique Guinn,Xavier Roshitha Ramisetty,Thomas P Giordano,Ivy O Poon

DOI: https://doi.org/10.3390/pharmacy12050144

2024-09-24

Abstract:Community pharmacies have unparalleled potential to increase access to pre-exposure prophylaxis medications (PrEP) for HIV prevention; however, only 17 out of 50 states in the United States have statewide authority for pharmacists to provide PrEP at community pharmacies. Few studies have reported on how pharmacists overcome the legislative barrier and provide PrEP services in restrictive pharmacy prescription states. The objective of this article is to identify the existing primary literature describing pharmacist PrEP services in the community in states with restrictive prescription authority. Methods: A systemic literature review was conducted to identify the primary literature that involved community pharmacy service and PrEP conducted in states that do not have expanded pharmacist prescriptive authority between 2000 to 2024. Results: Ten publications were identified, describing nine studies, including four interview and survey studies, three intervention reports, and two ongoing clinical trials. None of these studies have a control group. Most pharmacists provide PrEP services in the community through a collaborative practice agreement with a primary care provider. Conclusions: Future clinical studies with randomized controlled designs are required to test novel strategies in the education and implementation of pharmacy-led PrEP services in a community pharmacy setting to increase PrEP access.
Impact of an interdisciplinary patient care model and routine screening on clinical outcomes in patients with hepatitis C

Vincent Lam,Christine Dimaculangan

DOI: https://doi.org/10.24926/iip.v14i2.5114

2023-07-18

INNOVATIONS in pharmacy

Abstract:Testing for hepatitis C in hospital emergency departments (ED) and linkage to care to clinics have been reported to provide the most opportunity for screening patients and facilitating continuum of care. Treatment model initiatives have expanded to include telehealth services and open treatment capacity to non-physician providers, such as pharmacists. This study’s objective is to assess the impact of implementing automated routine screening for hepatitis C virus (HCV) and a clinical pharmacist into the interdisciplinary care model on HCV diagnosis and treatment outcomes. This retrospective cohort study compared outcomes in a pre-intervention and post-intervention group. Patients were screened and diagnosed with HCV at Jersey City Medical Center (JCMC) and completed linkage to care at JCMC Center for Comprehensive Care. Interventions were the implementation of automated routine HCV screening in the ED and addition of a clinical pharmacist to the interdisciplinary patient care model. Primary Endpoints analyzed the number of patients who have achieved sustained virologic response after 12 weeks of treatment (SVR12) and patients who have completed treatment with no reported record of SVR12. Secondary Endpoints analyzed the number of patients lost to follow-up, appointment type, time spent in appointments, and clinical pharmacist specialist interventions. Data was collected as categorical variables and chi-squared tests assessed if there were differences between the two samples. Data was collected from 46 patients in the pre-intervention group and 37 patients in the post-intervention group. Patients consisted of mostly males. Ages ranged from 27 to 83 years old. Race and ethnicities included Black, White, Asian, and Other. This study’s results show the positive impact on implementation of routine screening, telehealth services, and an interdisciplinary team approach to HCV diagnosis and management. Given the timeframe, it also shows the potential positive impact on these interventions during a global pandemic.
917. Accessible HCV Care for People Who Inject Drugs: Randomized Clinical Trial Comparing Low-Threshold Treatment at a Syringe Service Program Versus Facilitated Referral

Benjamin Eckhardt,Yesenia Aponte-Melendez,Chunki Fong,Shashi Kapadia,La Davis,Melinda Smith,Pedro Mateu-Gelabert,Kristen Marks,Kristen Marks

DOI: https://doi.org/10.1093/ofid/ofab466.1112

2021-11-01

Open Forum Infectious Diseases

Abstract:Abstract Background To achieve hepatitis C virus (HCV) elimination, treatment programs need to be developed to engage, treat, and cure people who inject drugs (PWID). Methods We present final data from the Accessible Care Trial for curing HCV in PWID. The randomized clinical trial compared on-site, low-threshold HCV treatment with care-coordination at a NYC syringe service program (Accessible Care) with facilitated referral to local providers through a patient navigation program (Usual Care). Eligible participants were HCV RNA+ and had injected drugs in the past 90 days. Participants were randomized 1:1 to the Accessible Care or Usual Care arm. The primary endpoint was achievement of sustained virologic response (SVR12) within 12 months of enrollment. Secondary endpoints examined rates HCV care cascade step completion from referral to clinician, attending clinical visit, baseline lab testing, treatment initiation, and cure. Results Among the 572 participants screened, 167 met eligibility criteria and were enrolled, with two excluded post-randomization (N=165). Demographics were similar with a median age of 41 years; 22% women; 59% Hispanic and 5% non-Hispanic black. At baseline, 84% of participants had injected drugs in the past 30 days with those averaging 22 injections/month, 70% were receiving either methadone or buprenorphine, 57% were recently homeless, 7% were HIV+, and 11% were HCV treatment experienced. In the intention-to-treat analysis, 55/82 (67.1%) of the Accessible Care arm and 19/83 (22.9%) of the Usual Care arm achieved SVR12 (p< 0.001). The SVR12 rates of those starting therapy were 55/64 (85.9%) and 19/22 (86.3%) in the two arms (p=0.96). Loss to follow-up (12.2% and 16.9%, p=0.51) was similar in the two arms. Significantly more participants in the Accessible Care arm achieved all steps in the care cascade with the greatest attrition in the Usual Care arm seen in referral to clinician and attending clinical visit. Conclusion Among HCV RNA+ PWID significantly higher rates of cure were achieved using the Accessible Care model focused on low-threshold, destigmatized, flexible HCV care compared to facilitated referral. To achieve HCV elimination, expansion of treatment programs specifically geared toward engaging PWID is paramount. Disclosures Benjamin Eckhardt, MD, MS, Gilead Sciences (Grant/Research Support) Shashi Kapadia, MD, Gilead Sciences Inc (Grant/Research Support) Kristen Marks, MD, Gilead Sciences (Grant/Research Support)

immunology,infectious diseases,microbiology
Hepatitis C antibody prevalence, correlates and barriers to care among people who inject drugs in Central California

Jenny E. Ozga,Jennifer L. Syvertsen,Robin A. Pollini

DOI: https://doi.org/10.1111/jvh.13677

2022-04-06

Journal of Viral Hepatitis

Abstract:Hepatitis C (HCV) infection among people who inject drugs (PWID) is a major public health concern. We examined correlates of HCV antibody (anti‐HCV) seropositivity and characteristics of prior HCV testing and treatment among PWID in Fresno, California, which has among the highest prevalence of injection drug use (IDU) in the U.S. We surveyed 494 peer‐recruited PWID (≥18 years of age) in 2016 about their experiences with HCV testing and treatment, and conducted HCV and HIV antibody testing for all participants. Bivariate analyses and multivariable logistic regressions were used to identify correlates of anti‐HCV seropositivity. A majority (65%) tested positive for anti‐HCV, with 32% of those being unaware of their HCV status. Anti‐HCV seroprevalence was independently and positively associated with older age (AOR=1.11 per year, 95% CI=1.06, 1.17), years injecting (AOR=1.08 per year, 95% CI=1.03, 1.13), distributive syringe sharing (AOR=2.76, 95% CI=1.29, 5.94), having syringes confiscated by police (AOR=2.65, 95% CI=1.22, 5.74), and ever trading sex (AOR=3.51, 95% CI=1.40, 8.81), and negatively associated with being Black/African American (non‐Hispanic) (AOR=0.06, 95% CI=0.01, 0.47). Prior HCV testing was associated with older age, ever getting syringes from a syringe services program, and having interactions with police. For those aware of their anti‐HCV seropositivity, only 11% had initiated treatment; reasons for not seeing a physician regarding diagnosis included not feeling sick (23%), currently using drugs/alcohol (19%), and not knowing where to go for HCV medical care (19%). Our findings highlight the importance of expanding community‐based access to sterile syringes alongside HCV testing and treatment services, particularly at syringe service programs where PWID may be more comfortable seeking testing and treatment.

gastroenterology & hepatology,infectious diseases,virology
Hepatitis C elimination in people living with HIV – the importance of biomedical and behavioural interventions

Daniela K Santen,Rachel Sacks‐Davis,Margaret Hellard

DOI: https://doi.org/10.1002/jia2.25589

2020-07-01

Journal of the International AIDS Society

Abstract:Hepatitis C virus (HCV) infects an estimated 71 million people, including over two million with HIV/HCV coinfection [1]. The World Health Organization (WHO) aims to eliminate HCV as a public health threat by 2030, reducing incidence by 80% and HCV‐related mortality by 65% from 2015 numbers. People living with HIV (PLHIV) are at six times higher odds of HCV infection than their HIV‐negative counterparts; coinfected people have three times the mortality of HCV‐monoinfected individuals [1, 2], and 12 times general population mortality, so are key to elimination [3]. HIV/HCV coinfection is common within vulnerable populations, including people who inject drugs (PWID), due largely to sharing injecting equipment, but also HIV‐positive gay and bisexual men (GBM), due largely to high‐risk sexual behaviour (often combined with drug use) [1].

immunology,infectious diseases
Using an intersectionality lens to explore barriers and enablers to hepatitis C point-of-care testing: a qualitative study among people who inject drugs and service providers

Guillaume Fontaine,Justin Presseau,Julie Bruneau,Cole Etherington,Isabella M. Thomas,Jui-Hsia Cleo Hung,Zack van Allen,Andrea M. Patey,Ayesha Kareem,Sameh Mortazhejri,Stine Bordier Høj,Geneviève Boyer-Legault,Jeremy M. Grimshaw

DOI: https://doi.org/10.1186/s12939-024-02209-0

2024-06-19

International Journal for Equity in Health

Abstract:Hepatitis C virus (HCV) infection is a significant global health burden, particularly among people who inject drugs. Rapid point-of-care HCV testing has emerged as a promising approach to improve HCV detection and linkage to care in harm reduction organizations such as needle and syringe programs. The objective of this study was to use an intersectionality lens to explore the barriers and enablers to point-of-care HCV testing in a needle and syringe program.

public, environmental & occupational health
Implementation Science of Integrating Pre-Exposure Prophylaxis in Pharmacist-Led Services in the United States

Christina Chandra,Alexis F Hudson,Daniel I. Alohan,Henry N. Young,Natalie D. Crawford

DOI: https://doi.org/10.1007/s11904-024-00700-5

IF: 5.495

2024-05-23

Current HIV/AIDS Reports

Abstract:Racial inequities in HIV in the United States (US) are pervasive. Pre-exposure prophylaxis (PrEP) is one of the most effective yet underutilized HIV prevention strategies, and stark inequities in PrEP uptake exist. Lack of access to PrEP clinics is a major barrier to access that could be overcome by integrating pharmacists into the provision of PrEP services including prescribing and dispensing.

infectious diseases
Early‐onset sarcoidosis mimicking refractory cutaneous histiocytosis

S. Ohga,Kiyomi Ichino,K. Urabe,M. Ishimura,H. Takada,R. Nishikomori,M. Furue,T. Hara

DOI: https://doi.org/10.1002/pbc.21173

2008-03-01

Pediatric Blood & Cancer

Abstract:A 10‐year‐old female was diagnosed as having early‐onset sarcoidosis (EOS) after a prolonged skin disease. A granuloma emerged on the face at age 2 and massive lesions extended to the rest of the body. Repeated biopsies indicated histiocytic proliferation. At age 7, fever, disseminated macular eruptions, and multinucleated giant cells in the bone marrow prompted vinblastine and prednisolone therapy. Five months after stopping therapy, hypercalcemic crisis occurred along with fever, cytopenias, and interferon‐γ‐nemia indicating a macrophage activation syndrome. A biopsy of nodules confirmed the diagnosis of sarcoidosis. The atypical EOS should be differentiated from histiocytosis. Pediatr Blood Cancer 2008;50:723–726. © 2007 Wiley‐Liss, Inc.
Coproduction of Low-Barrier Hepatitis C Virus and HIV Care for People Who Use Drugs in a Rural Community: Brief Qualitative Report

Shoshana H Bardach,Amanda N Perry,Elizabeth Eccles,Elizabeth A Carpenter-Song,Ryan Fowler,Erin M Miers,Anais Ovalle,David de Gijsel

DOI: https://doi.org/10.2196/47395

2023-09-21

Journal of Participatory Medicine

Abstract:Background: People who inject drugs are experiencing syndemic conditions with increasing risk of infection with hepatitis C (HCV) and HIV. However, rates of accessing HCV and HIV testing and treatment among people who inject drugs are low for various reasons, including the criminalization of drug use, which leads to a focus on treating drug use rather than caring for drug users. For many people who inject drugs, health care becomes a form of structural violence, resulting in traumatic experiences, fear of police violence, unmet needs, and avoidance of medical care. There is a clear need for novel approaches to health care delivery for people who inject drugs. Objective: This study aimed to analyze the process of a multidisciplinary team—encompassing health care professionals, community representatives, researchers, and people with lived experience using drugs—that was formed to develop a deep understanding of the experiences of people who inject drugs and local ecosystem opportunities and constraints to inform the cocreation of low-barrier, innovative HCV or HIV care in a rural community. Given the need for innovative approaches to redesigning health care, we sought to identify challenges and tensions encountered in this process and strategies for overcoming these challenges. Methods: Analysis was based on an in-depth review of meeting notes from the project year, followed by member-checking with the project team to revise and expand upon the challenges encountered and strategies identified to navigate these challenges. Results: Challenges and tensions included: scoping the project, setting the pace and urgency of the work, adapting to web-based work, navigating ethics and practice of payment, defining success, and situating the project for sustainability. Strategies to navigate these challenges included: dedicated effort to building personal and meaningful connections, fostering mutual respect, identifying common ground to make shared decisions, and redefining successes. Conclusions: While cocreated care presents challenges, the resulting program is strengthened by challenging assumptions and carefully considering various perspectives to think creatively and productively about solutions.
Kinetic model of progression of cutaneous melanoma population

D. Gutkowicz–Krusin,H. Rabinovitz

DOI: https://doi.org/10.1097/CMR.0b013e3282f120bf

2007-12-01

Melanoma Research

Abstract:A kinetic model for progression of a population of cutaneous melanomas through categories defined by the range of Breslow thickness, with melanomas in situ (MIS) in category 0, and melanomas with Breslow thickness ≥2 mm in category 3, is described. The model assumes that all melanomas start out in category 0; this category is further subdivided into indolent and progressing melanomas. Steady-state solutions for the distributions of excised melanomas were found. Depending on the proportion of indolent MIS, these solutions predict very different distributions of excised melanomas and melanoma mortality, when either frequency of examinations by physicians or sensitivity to melanoma is changed. Although it is not currently possible to differentiate between indolent and progressing MIS either clinically or histologically, solutions of this kinetic model can be used to determine the proportion of such indolent lesions in a population-based study. The steady-state solutions of the kinetic model can be used to analyze melanoma progression in any stable patient population, in which the total number of melanomas detected per year is either stable or varies slowly. As an example, melanoma progression is analyzed using the American Cancer Society estimates of melanoma incidence and mortality. For a fixed incidence rate, melanoma mortality and melanoma treatment cost in the USA could be significantly reduced by increasing the biopsy sensitivity of physicians to in-situ and thin-invasive melanomas.

Dr. Sullivan's response to Dr. Toogood's editorial.

Retrospective biomonitoring: a hundred years of environmental pollution at selected areas in Slovakia.

Refinement of reference limits for alanine aminotransferase in the Korean elderly population.

Community Pop‐Up Clinic: Cascade of Care and HCV Treatment of Vancouver's Inner‐City PWID Populations

Challenges and Opportunities for Treating Hepatitis C Amongst People Who Use Drugs: Experience of an Integrated Mobile Clinic in Baltimore City

An Analysis of Social Determinants of Health and Their Implications for Hepatitis C Virus Treatment in People Who Inject Drugs: The Case of Baltimore

Improving Access to Hepatitis C Treatment Using Clinical Pharmacist Services in an Uninsured, At-Risk Population at a Community Health Center

High prevalence of hepatitis B virus susceptibility among persons undergoing community-based hepatitis C virus treatment

2942. Successful Screening, Linkage to Care, and Treatment of Hepatitis C in a Tiny Shelter Encampment on Veterans Affairs Grounds

Acceptability and Effectiveness of Hepatitis C Care at Syringe Service Programs for People Who Inject Drugs in New York City

Findings from a Project Which Established Hepatitis C Point-of-Care Testing and Linkage to Care at a Homelessness Service in Adelaide, Australia, 2021–2022

A Review of Studies on HIV Pre-Exposure Prophylaxis in Community Pharmacies in States with Restrictive Pharmacist Prescription Authority in the United States

Impact of an interdisciplinary patient care model and routine screening on clinical outcomes in patients with hepatitis C

917. Accessible HCV Care for People Who Inject Drugs: Randomized Clinical Trial Comparing Low-Threshold Treatment at a Syringe Service Program Versus Facilitated Referral

Hepatitis C antibody prevalence, correlates and barriers to care among people who inject drugs in Central California

Hepatitis C elimination in people living with HIV – the importance of biomedical and behavioural interventions

Using an intersectionality lens to explore barriers and enablers to hepatitis C point-of-care testing: a qualitative study among people who inject drugs and service providers

Implementation Science of Integrating Pre-Exposure Prophylaxis in Pharmacist-Led Services in the United States

Early‐onset sarcoidosis mimicking refractory cutaneous histiocytosis

Coproduction of Low-Barrier Hepatitis C Virus and HIV Care for People Who Use Drugs in a Rural Community: Brief Qualitative Report

Kinetic model of progression of cutaneous melanoma population